Department of Surgery, Memorial Healthcare System, Hollywood, Florida.
Office of Human Research, Memorial Healthcare System, Hollywood, Florida.
J Surg Res. 2022 Sep;277:17-26. doi: 10.1016/j.jss.2022.03.018. Epub 2022 Apr 19.
Textbook oncologic outcome (TOO) is a composite outcome measure attained when all desired short-term quality metrics are met following an oncologic operation. The objective of this study was to determine the incidence of TOO and its impact on the overall survival (OS) among patients with invasive ductal carcinoma (IDC) following modified radical mastectomy (MRM).
The 2004-2017 National Cancer Database was queried for patients with non-metastatic IDC who underwent MRM. TOO was defined as having attained five metrics: resection with negative microscopic margins, American Joint Committee on Cancer compliant lymph node evaluation (n ≥ 10), no prolonged length of stay (50 percentile by year), no 30-d readmission, and no 30-d mortality. OS was defined as the time in months between the date of diagnosis and the date of death or last contact.
A total of 75,063 patients were identified, of which 40.8% achieved TOO. The TOO patients had a lower median age and were more likely to be White, privately insured, and without comorbidities. In terms of facility characteristics, patients with TOO were more likely to be seen in comprehensive community cancer programs with a high case-volume per year. The TOO group had a statistically significant higher median OS compared to the non-TOO group (165.6 versus 142.2 mo; P < 0.001). On multivariate analysis TOO was independently associated with a reduced risk of death (HR = 0.82; P < 0.001).
TOO is achieved in approximately 41% of patients undergoing MRM for IDC. Achieving TOO is associated with improved median OS and reduced risk of death. TOO therefore merits further attention in efforts to improve surgical outcomes.
教科书式肿瘤学结局(TOO)是指在接受肿瘤手术后,所有期望的短期质量指标都得到满足时所获得的综合结局衡量标准。本研究的目的是确定在接受改良根治性乳房切除术(MRM)后浸润性导管癌(IDC)患者中,TOO 的发生率及其对总体生存率(OS)的影响。
从 2004 年至 2017 年的国家癌症数据库中查询接受 MRM 的非转移性 IDC 患者。TOO 的定义为达到以下 5 项指标:显微镜下切缘阴性的切除、符合美国癌症联合委员会(AJCC)要求的淋巴结评估(n≥10)、无延长住院时间(按年度划分的第 50 百分位数)、无 30 天再入院、无 30 天内死亡。OS 定义为从诊断日期到死亡或最后一次随访的时间(以月为单位)。
共确定了 75063 例患者,其中 40.8%的患者达到了 TOO。TOO 患者的中位年龄较低,且更有可能是白人、私人保险和无合并症。在医疗机构特征方面,TOO 患者更有可能在每年接受大量病例的综合性社区癌症项目中就诊。与非 TOO 组相比,TOO 组的中位 OS 有显著提高(165.6 与 142.2 个月;P<0.001)。多变量分析显示,TOO 与降低死亡风险独立相关(HR=0.82;P<0.001)。
在接受 IDC 改良根治性乳房切除术的患者中,约有 41%达到了 TOO。达到 TOO 与改善中位 OS 和降低死亡风险相关。因此,TOO 值得在提高手术结果的努力中进一步关注。